Scoop.it

As states reopen, contact tracing — locating and testing people known to have been in close contact with someone who has COVID-19 — will be an important tool to help contain further spread of illness. But how does it work, and what do you need to know about it?

Source: www.health.harvard.edu

A recent report analyzing claims data identified virtual-care use cases estimates that could comprise roughly 20% of all Medicare, Medicaid and commercial spend across outpatient, office and home health.

Source: www.mobihealthnews.com

Depuis le début de la crise sanitaire, 1814 habitants de Seine-et-Marne et de l’Essonne ont été suivis par la plateforme Terr’e-Santé, composée de professionels de santé. Ils sont encore 820 à être sous surveillance.

Source: www.leparisien.fr

The World Health Organization is resuming its trial of hydroxychloroquine, the malaria drug backed by President Donald Trump to combat the deadly coronavirus, after temporarily halting research over safety concerns.

The Data Safety Monitoring Board decided there was no reason to discontinue the international trial after reviewing available data on the drug, WHO Director-General Tedros Adhanom Ghebreyesus said during a press conference Wednesday at the agency’s Geneva headquarters.

“The executive group received this recommendation and endorsed the continuation of all arms of solidarity trial including hydroxychloroquine,” he said.

On May 25, WHO announced it had temporarily suspended its trial of the drug over safety concerns. The announcement came days after a study published in medical journal The Lancet found that hospitalized Covid-19 patients treated with hydroxychloroquine had a higher risk of death than those who didn’t take it. That study is now being reexamined.

The suspension spurred French drugmaker Sanofi and others to temporarily halt recruitment for their own trials looking at the drug.

There’s no evidence that any drug actually reduces the mortality in patients who have Covid-19, WHO officials said Wednesday.

Tedros said the safety board will continue to closely monitor the safety of all therapeutics being tested in its trials, which involve more than 3,500 patients across 35 countries.

Source: www.cnbc.com